Here are six quick facts:
1. The shares were sold at an average price of $24.56, for a total value of $1.15 million.
2. Dr. Kostuik now directly owns 190,114 shares in the company, valued at approximately $4.6 million.
3. Dr. Kostuik is a co-founder and CMO of K2M.
4. K2M has a one-year low of $12.31 and a one-year high of $26.29.
5. The stock has a 50-day moving average of $24 and a 200-day moving average of $21.
6. K2M’s market cap is $995.34 million.
More articles on devices:
Michael Turpin joins K2M board of directors — 5 key notes
22 things to know about Stryker
FDA grants Centinel Spine allogeneic bone graft indications for lumbar spinal fusion line — 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
